The CEO of ABLE member Serum Institute of India, Mr Adar Poonawalla, in an exclusive interview with news channel NDTV 24X7 recently had revealed several details about the Coronavirus vaccine. 
In the interaction with NDTV, Mr Poonawalla had said that the coronavirus vaccine developed at the Oxford University will be in India by November and will ultimately cost Rs 1,000 or less  and it could take up to two years to inoculate all the people in India.
The manufacturing of the Covishield vaccine had started parallelly with the clinical trials, the first phase of which got positive results. The trial results published in The Lancet medical journal this week said the vaccine had a favourable response in the first phase of clinical trials. It did not prompt any serious side effects and elicited antibody and T-cell immune responses, reports NDTV. 
Mr Poonawalla told NDTV, “We are confident of going on to the Phase 3 trials in India in August and we forecast that it will take probably two to two-and-half months to complete. By November, we hope to launch the vaccine if the trials are positive and if the Drug Controller of India blesses it and says it is safe and effective.” 
NDTV has also revealed through its interaction with Mr Poonawalla that along with the Indian population, half the stock of Covishield manufactured at the Serum Institute will be exported, which would mean that out of roughly 60 million vials made each month, India will get 30 million.
 (Source & Credit: NDTV)

Mr Poonawalla had told NDTV that the vaccine will take probably two to two-and-half months to complete. He is hopeful that the vaccine will be launched by November, if the trials are positive and if the regulatorDCGI approves it.